Form 8-K - Current report:
SEC Accession No. 0001326110-26-000036
Filing Date
2026-04-09
Accepted
2026-04-09 07:39:06
Documents
13
Period of Report
2026-04-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibrx-20260409.htm   iXBRL 8-K 30407
2 EX-99.1 ibrx-2026498xkexhibit991.htm EX-99.1 20843
6 IMMUNITYBIO LOGO immunitybio-logox2024xcoloa.jpg GRAPHIC 31902
  Complete submission text file 0001326110-26-000036.txt   217905

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ibrx-20260409.xsd EX-101.SCH 1807
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ibrx-20260409_lab.xml EX-101.LAB 21876
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ibrx-20260409_pre.xml EX-101.PRE 12528
16 EXTRACTED XBRL INSTANCE DOCUMENT ibrx-20260409_htm.xml XML 2718
Mailing Address 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121
Business Address 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 (844) 696-5235
ImmunityBio, Inc. (Filer) CIK: 0001326110 (see all company filings)

EIN.: 431979754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37507 | Film No.: 26849833
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)